NanoViricides (NNVC) filed a preliminary prospectus late Friday with the US Securities and Exchange Commission for the potential sale of up to $50 million in securities through a mixed shelf offering from time to time.
The company said it plans to use the net proceeds from offering for general corporate purposes, including capital expenditure and working capital.